2025-02-24 Steering Committee Meeting Notes

Stakeholder group

SHIELD organization

Name of SHIELD member

organization designation

Industry Entity

Labgnostic, Inc.

Steve Box

primary

NEED NEW

alternate

Epic

Dan Rutz

primary

alternate

Biomerieux

Xavier Gansel

primary

alternate

Roche

Nick Decker

primary

Roche

Yue Jin

alternate

Healthcare Provider

Indiana University/Indiana University Health/Association for Molecular Pathology

Mehdi Nassiri, MD

primary

University of Wisconsin-Madison

Andrea Pitkus, PhD, MLS(ASCP)CM, FAMIA

primary

UT Southwestern Medical Center

Hung Luu

primary

UNMC

Scott Campbell

primary

OPEN

OPEN

primary

Sonic Healthcare

Eric Crugnale

primary

Former Quest Diagnostics - OPEN?

Collom, Craig D

primary

Patient Advocate

 OPEN?

Stacy Lange

individual

Standards Organization

SNOMED International

Jim Case

primary

Monica Harry

alternate

Regenstrief Institute

Marjorie Rallins

primary

Eza Hafeza

alternate

HL7

Julia Skapik

primary

alternate

Professional Organization

Association of Public Health Laboratories

Riki Merrick - regrets

primary

Christina Gallegos

alternate

Graphite Health

Stan Huff

primary

alternate

CAP

Raj Dash-regrets

primary

alternate

AMP

Robyn Temple

primary

alternate

Governmental - non Voting

CMS

Michael Smalara

primary

Open

alternate

ASTP/ONC

Sara Armson

primary

alternate

CDC

Hubert Vesper (/DDNID/NCEH/DLS)

primary

Jasmine Chaitram

alternate

NLM

 John Snyder

primary

alternate

FDA

 Keith Campbell

primary

Victoria Derbyshire

alternate

Quorum evaluation (two-thirds (2/3) of the Voting Representatives shall be necessary to constitute a quorum for the transaction of business)

Currently we have 18 named members, so 2/3 = 12 (excluding chair and government members).

# of voting member per charter: 13 - 21

# of non-voting members per charter: 7

Open Meeting

 1:08 PM ET

SHIELD Charter Updates as shared via email sent to SC members on

• Proposed Charter Updates Feb 2025

Note: Changes to the Charter require unanimous approval by the Steering Committee

SHIELD membership requests from last call as shared via email sent to SC members on February 1, 2025

eVote passed - the below are approved as new SHIELD Members:

• Steven Emrick

• Carmen Pugh former Labcorp and long time lab professional (as individual rather than a CDC representative)

• Mark Ediger as indivdual

• Natalee Agassi as representative for Oracle Cerner

• Matthew Allison as representative for Quest Diagnostics

Steering Committee Membership and Officer Roles

• These slots are potentially open:

  • 2 Healthcare Provider (Nirmala resigned end of December, Craig has not been participating on calls, would have to consider vote to terminate his SC participation, if we want to add more than one) = Have interest from these folks:

    • Jeffrey Smith from Kaiser Permanente

    • Carmen Pugh as individual

    • Mark Ediger as indivudal

  • 1 Patient Advocate (Stacy also resigned via email for now)

• Invite these folks to the next SC call and fill the open position first?

• Chair and Vice Chair terms

  • First of 2 allowed consecutive terms expires 3/14/2025

  • Nomination period expired 2/12/2025

  • Votes have to be held before expiration, so on 3/10/2025 call - Interest received from:

    • Chair:

      • Riki Merrick

      • Andrea Pitkus

    • Vice Chair:

      • Eric Crugnale

      • Riki Merrick

      • Andrea Pitkus

• Composition of Steering Committee changes?

  • Expand by 2 members ?

Review Items

LIDR White Paper was open for SC review and comment until Feb 21, 2025

https://www.jmdjournal.org/article/S1525-1578(21)00327-5/fulltext AMP paper.

Conferences

AMIA November 15 - 19 in Atlanta, GA - proposals are open till 3/19 AMIA 2025 Annual Symposium Call for Participation

LOINC 7-10 October in Montreal, Canada - proposals are open till 3/30 2025 LOINC Conference - Presentations – LOINC

ASCLS got accepted - waiting for exact date/time

ADLM got submitted - waiting for response

Notes from the FDA Collaborative Community Panel are here: FDA CDRH Collaborative Community Panel

Other presentations to folks at FDA?

• Data Standards Review Committee of the FDA – work with Helena Sviglin

• FDA Scientific Computing Board (SCB)

• Compass group lab

Review Working Groups progress

THANK YOU to all the WG Chairs for their effort in moving SHIELD work forward!!!

Setting milestones for deliverables should be NEXT for WGs: they will be captured here: SHIELD WG Deliverables and Milestone Grid

• Laboratory Interoperability Data Registry (LIDR) Working Group

  • Pilot Group met.

• IVD Data Hub

  • Exploring finding funding opportunities - current talks with Truveta (EHR data and analytics | Truveta )

• Standards Updates and Vocabulary Working Group

  • Have 2 new Co-chairs: Steven Emrick and Julia Skapik and Raj will keep supporting for transition

  • Call later this week to restart

  • Review the LRI

• Communications and Branding Working Group

  • SHIELD Membership Survey is open 2/3 - 2/24/2025 Extended 31 responses. Will review on Wednesday’s call to summarize for next steering.

  • AMIA proposal. Will any SHIELD members be attending? Could the LIDR White Paper be Presented as unpublished work? Options: Paper (15 mins), podium abstract (15 mins), panel discussion (4 attendees, moderator, 90 mins). (Steve Emrick, Julia, Marjorie willing to help). Would it be an option to have virtual presenters? Eric to email.

  •  

Roadmap section updates in response to ONC comments on the SHIELD roadmap

1. The roadmap mission section describes a broad vision of lab interoperability. However, the roadmap proposed solution is limited to the FDA use cases around In-vitro diagnostics (IVD) data, specifically populating the IVD data hub.  ONC suggests clearly describing the roadmap scope so the proposed solutions can be discussed within that context.

Updated language draft: Roadmap update: ONC Feedback

maybe add one more sentence or add a reference to the key consideration number for the IVD Datahub (Consideration 4) into these sentences. (change approved in principle.)

Discussion:

• Updated roadmap:

• Also need to remove the duplicate words “for the” in the last sentence

• Anything else needed on this one?

2. The roadmap identifies training and education needs around using LOINC as a barrier to interoperability. ONC suggests clarifying how the roadmap addresses this barrier. ONC recognizes that terminologies require training and education, and replacing LOINC with another standard will not address the barrier.

Update from Standards and Vocab WG about re-write of this section - from their March 18^th call (notes here, recording here)

1. Concepts around Healthcare IT (HIT) standards needs to be conveyed earlier in training for healthcare providers as use and application of standards in vended applications is the major gap.

2. Decision making to use Health IT standards are less likely left up to IT analysts as they mainly follow the requirements and then they generally use vendor supplied implementation guidance. However, a vendor may not support functionality for standards or only partially support.

3. Regulatory requirements (such as CLIA) may pose a hurdle to implementation of data standards.

4. Implementation guidance is often not well read. Training resources may not be well publicized or readily available. Perhaps conformance testing tools need to be made more widely available?

5. What might be helpful is to look at standards implementation from a data lifecycle standpoint across all users (end to end across ecosystem), rather than just training on a single standard for a single use case.

6. Last paragraph on page 4 of the road map final version could be augmented with these points.

Discussion:

• Need to find the exact space for these points, too

3. There are several solutions proposed, including repositories and tools, which need to be further evaluated before ONC could fully support the roadmap.  ONC suggests the roadmap be updated to include details around feasibility, scalability and how the proposed changes can be integrated into the current laboratory ecosystem (e.g., regulation and industry).

Identify components that could improve the ecosystem infrastructure, and then highlight the places where these components can be advanced / sustained or made easier to implement. Would SHIELD be willing to consider to provide an example implementation - create the structures and bound terminologies to showcase how each element would be properly represented be working.

For each of the Consideration sections we could certainly add a section on feasibility / requirements (e.g. continued funding for LIDR, better describing the intended use of ANY data element added, overall goal of LIDR, clearly delineate what is commonly used and is minimum, provide best practice and alternatives (non-preferred) - example would be metadata around the value sets in VSAC (curation / usage etc) to be able to ascertain quality) and highlight that other mechanisms are needed to achieve for adoption.

Antimicrobial result reporting

Placeholder to get back to later

Related work at HL7 Europe:

Next calls

All SHIELD Calls

• February 25^th (Andrea to host - Christina to support)

• March 25^th

General Updates: 2024 - WG Chairs please make sure we have material for updates (at least notes we can link to)

Special Topic:

• March 11^th - Synensys Report update

Steering Committee:

• March 10^th will voting be 1st or 2nd half (preferred)?

• March 24^th

• Not scheduled after this - decide on new day/time (else April 21 is Easter Monday)

• https://www.jmdjournal.org/article/S1525-1578(21)00327-5/fulltext

Adjourned

 201 PM ET